Search results for "antico"

showing 10 items of 736 documents

Ketorolac, diclofenac, and ketoprofen are equally safe for pain relief after major surgery

2002

Background Ketorolac is approved for the relief of postoperative pain but concerns have been raised over a possible risk of serious adverse effects and death. Two regulatory reviews in Europe on the safety of ketorolac found the data were inconclusive and lacked comparison with other non-steroidal anti-inflammatory drugs. The aim of this study was to compare the risk of serious adverse effects with ketorolac vs diclofenac or ketoprofen in adult patients after elective major surgery. Methods This prospective, randomized multicentre trial evaluated the risks of death, increased surgical site bleeding, gastrointestinal bleeding, acute renal failure, and allergic reactions, with ketorolac vs di…

AdultMaleKetoprofenGastrointestinal bleedingmedicine.medical_specialtyDiclofenacAnalgesicBlood Loss Surgicallaw.inventionDrug HypersensitivityDiclofenacRandomized controlled trialRisk FactorslawmedicineHumansCyclooxygenase InhibitorsProspective StudiesAdverse effectAgedAged 80 and overPain Postoperativebusiness.industryAnti-Inflammatory Agents Non-SteroidalAnticoagulantsAcute Kidney InjuryMiddle Agedmedicine.diseaseSurgerybody regionsKetorolacClinical trialstomatognathic diseasesAnesthesiology and Pain MedicineKetoprofenAnesthesiaFemalebusinessKetorolacmedicine.drug
researchProduct

Levetiracetam in the prophylaxis of migraine with aura: a 6-month open-label study.

2006

OBJECTIVE: To evaluate the efficacy of levetiracetam as prophylactic treatment for migraine with aura with high frequency of attacks. BACKGROUND: Migraine with aura with high frequency of attacks could represent a very demanding therapeutic problem. Efficacy of the antiepileptic drug, lamotrigine, has been reported in this form of migraine. Levetiracetam is a new antiepileptic drug with an excellent tolerability profile. Mechanisms of action of this drug remain largely unknown, but recently, it has been shown to exert inhibitory effects on neuronal-type calcium channels. METHODS: We performed a small open-label trial treating 16 patients affected by migraine with aura with high frequency of…

AdultMaleLevetiracetamAuraMigraine with AuraLamotrigineMedicineHumansPharmacology (medical)Prospective StudiesProspective cohort studyPharmacologybusiness.industryMiddle Agedmedicine.diseasePiracetamMigraine with auraTolerabilityMigraineAnesthesiaAnticonvulsantsFemaleNeurology (clinical)Levetiracetammedicine.symptombusinessSomnolencemedicine.drugClinical neuropharmacology
researchProduct

Subregional Pathology of the Amygdala Complex and Entorhinal Region in Surgical Specimens From Patients With Pharmacoresistant Temporal Lobe Epilepsy

2000

The hippocampus, amygdala complex, and entorhinal region represent anatomically linked limbic structures of the mesiotemporal lobe. Chronic seizures and mnestic deficits in patients with pharmacoresistant mesial temporal lobe epilepsy (TLE) appear to correlate with distinct patterns of histopathological alterations in these areas. The complex anatomical organization of the amygdala and entorhinal region, however, render a detailed neuropathological evaluation of surgical specimens difficult. In this study, we present a combined cytoarchitectonical, pigmentarchitectonical, myelinarchitectonical, and immunohistochemical reconstruction of the amygdala, entorhinal region, and hippocampus from s…

AdultMalePathologymedicine.medical_specialtyAdolescentDrug ResistanceHippocampusAutopsyAmygdalaPathology and Forensic MedicineTemporal lobeCentral nervous system diseaseCellular and Molecular NeuroscienceEpilepsyBasal (phylogenetics)medicineEntorhinal CortexHumansGliosisSclerosisGeneral MedicineMiddle AgedAmygdalamedicine.diseaseTemporal LobeLobemedicine.anatomical_structureEpilepsy Temporal Lobenervous systemNeurologyChild PreschoolAnticonvulsantsFemaleNeurology (clinical)Psychologypsychological phenomena and processesJournal of Neuropathology & Experimental Neurology
researchProduct

Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in pati…

2012

Summary Von Willebrand disease (VWD) is an inherited bleeding disorder caused by the quantitative or qualitative deficiency of von Willebrand factor (VWF). Replacement therapy with plasma-derived VWF/factor VIII (FVIII) concentrates is required in patients unresponsive to desmopressin. To assess the efficacy, safety and ease of use of a new, volume-reduced (VR) formulation of VWF/FVIII concentrate Haemate® P in patients requiring treatment for bleeding or prophylaxis for recurrent bleeding or for invasive procedures. Pharmacoeconomic variables were also recorded. Data were analysed using descriptive statistics. This was a multicentre, prospective, observational study. Consecutively enrolled…

AdultMalePediatricsmedicine.medical_specialtyAdolescentBlood Loss SurgicalSevere diseaseHemorrhageSettore MED/15 - Malattie Del SangueYoung AdultVon Willebrand factorCost of Illnesshemic and lymphatic diseaseshemophiliavon Willebrand FactorVon Willebrand diseasemedicineHumansIn patientProspective StudiesDesmopressinAdverse effectChildGenetics (clinical)AgedFactor VIIIbiologybusiness.industryDrug SubstitutionAnticoagulantsHematologyGeneral MedicineMiddle Agedmedicine.diseaseResponse to treatmentHospitalizationvon Willebrand DiseasesItalyChild Preschoolbiology.proteinPasteurizationObservational studyFemalebusinessmedicine.drug
researchProduct

Zonisamide in children and young adults with refractory epilepsy: an open label, multicenter Italian study

2009

Summary Purpose To report on the first multicenter Italian experience with zonisamide as an add-on drug for refractory generalised or partial epilepsy in children, adolescents and young adults. Methods The patients were enrolled in a prospective, add-on, open-label treatment study from eight Italian centres for children and adolescent epilepsy care. Eighty-two young patients (45 males, 37 females), aged between 3 and 34 years (mean 13.1 years), all affected by partial (47) or generalised (35) refractory epilepsy, were enrolled in the study. ZNS was added to the baseline therapy at a starting dose of 1 mg/kg/day twice daily. This dose was increased by 2 mg/kg every 1–2 weeks over a period of…

AdultMalePediatricsmedicine.medical_specialtyAdolescentmedicine.medical_treatmentAntiepileptic drugsZonisamideIrritabilityStatistics NonparametricEpilepsyYoung AdultRefractorymedicineHumansNonparametricYoung adultAdverse effectPreschoolChildNeurologic ExaminationEpilepsybusiness.industryStatisticsElectroencephalographyDrug ToleranceIsoxazolesmedicine.diseaseMagnetic Resonance ImagingSettore MED/39 - Neuropsichiatria InfantileEpilepsy; Zonisamide; Pediatric epilepsy; Antiepileptic drugsAnticonvulsantTolerabilityNeurologyItalyZonisamideChild PreschoolAnticonvulsantsFemaleNeurology (clinical)medicine.symptombusinessPediatric epilepsyAntiepileptic drugs; Epilepsy; Pediatric epilepsy; Zonisamide; Adolescent; Adult; Anticonvulsants; Child; Child Preschool; Drug Tolerance; Electroencephalography; Epilepsy; Female; Follow-Up Studies; Humans; Isoxazoles; Italy; Magnetic Resonance Imaging; Male; Neurologic Examination; Statistics Nonparametric; Young Adult; Neurology; Neurology (clinical)medicine.drugFollow-Up Studies
researchProduct

Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy

2004

Purpose: To evaluate the efficacy and safety of levetiracetam (LEV) in refractory crypto/symptomatic, partial or generalised epilepsy in children, adolescents and young adults. Methods: We performed a prospective open label add-on study in 99 patients (age 12 months to 32 years, mean 14 years) with partial or generalised, crypto/symtpomatic seizures. Levetiracetam was added to no more than two baseline AEDs and the efficacy was rated according to seizure type and frequency. Results: LEV was initiated at the starting dose of 10 mg/kg/day with 5-day increments up to 50 mg/kg/day, unless it was not tolerated. Concomitant therapy was generally not modified throughout the study. After a mean fol…

AdultMalePediatricsmedicine.medical_specialtyAdolescentmedicine.medical_treatmentlevetiracetamefficacyIrritabilityStatistics NonparametricEpilepsyDOUBLE-BLINDantiepileptic drugmedicineHumansprospective trialProspective StudiesChildAdverse effectChi-Square DistributionEpilepsybusiness.industryInfantmedicine.diseasePiracetamAnticonvulsantNeurologyTolerabilityEpilepsy in childrenChild PreschoolAnesthesiaEpilepsy syndromesFemaleTRIALNeurology (clinical)Levetiracetammedicine.symptomtolerability PARTIAL SEIZURESbusinessFollow-Up Studiesmedicine.drug
researchProduct

Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut syndrome

2011

Background:  To report on the first multicenter Italian experience with rufinamide as adjunctive drug in children, adolescents and young adults with refractory childhood-onset epileptic encephalopathies other than Lennox-Gastaut syndrome. Methods:  Thirty-eight patients (19 males, 19 females), aged between 4 and 34 (mean 13.7 ± 8.3, median 12.5), all affected by different types of childhood-onset refractory epileptic encephalopathies other than Lennox-Gastaut syndrome, were treated with rufinamide as adjunctive drug for a mean period of 11.4 months (range 3-26 months). Results:  Fifteen of 38 patients (39.5%) had a ≥50% seizure reduction in co…

AdultMalePediatricsmedicine.medical_specialtyAdolescentrufinamideRufinamideIrritabilityrefractory seizures; rufinamide; epileptic encephalopathies-childhoodYoung AdultRefractoryepileptic encephalopathies-childhoodrefractory seizuresrufinamideMedicineHumansYoung adultAdverse effectChildPreschoolepileptic encephalopathies-childhoodBrain DiseasesEpilepsybusiness.industryEpileptic encephalopathies-childhood; Refractory seizures; RufinamideTriazolesmedicine.diseaseSettore MED/39 - Neuropsichiatria Infantilerefractory seizuresMigraineepileptic encephalopathies-childhood refractory seizures rufinamideNeurologyAnesthesiaChild PreschoolVomitingAnticonvulsantsFemaleNeurology (clinical)medicine.symptombusinessEpileptic encephalopathies-childhood; Refractory seizures; Rufinamide; Adolescent; Adult; Anticonvulsants; Brain Diseases; Child; Child Preschool; Epilepsy; Female; Humans; Male; Triazoles; Young Adult; Neurology (clinical); NeurologyLennox–Gastaut syndromemedicine.drug
researchProduct

Immunonephelometric determination of the C4b-binding protein.

1993

A fully mechanised immunonephelometric method for the rapid and specific determination of C4b-binding protein (C4b-BP) in citrated plasma is described. The method utilizes commercially available rabbit antiserum against human C4b-BP and a nephelometer analyser. A single determination can be performed within 6 min, requiring 80 microliters sample volume. The measuring range is about 10 to 200% of normal C4b-BP. Precision is characterized by intraassay coefficients of variation between 1.5% and 2.8%, and interassay coefficients of variation between 4.0% and 4.6% for the same C4b-BP concentrations. The nephelometry of C4b-BP was correlated with electroimmunodiffusion (Laurell technique; r = 0.…

AdultMalePercentileImmunodiffusionAnalytical chemistryAdministration Oralchemical and pharmacologic phenomenaFibrinogenRabbit antiserumNephelometry and TurbidimetryBlood plasmamedicineComplement C4bHumansAgedGlycoproteinsInflammationComplement Inactivator ProteinsChromatographyChemistryC4b-binding proteinHeparinHealthy subjectsAnticoagulantsHematologyMiddle AgedEvaluation Studies as TopicFemaleCarrier ProteinsQuantitative analysis (chemistry)Nephelometrymedicine.drugThrombosis research
researchProduct

Interruption of the enterohepatic circulation of phenprocoumon by cholestyramine

1977

The effect of cholestyramine (12 gm/day divided into 3 doses) on the pharmacokinetics and pharmacodynamics of a single intravenouse dose (30 mg) of phenprocoumon was studied in 6 normal subjects. Cholestyramine treatment led to an increase in the rate of elimination of phenprocoumon in all. Total clearance increased 1.5- to 2-fold. The total anticoagulant effect per dose was considerably reduced during treatment with cholestyramine. Binding studies in vitro showed that phenprocoumon is strongly bound to cholestyramine and that at a given cholestyramine concentration the percentage of phenprocoumon bound remained constant over a large concentration range of phenprocoumon. The results suggest…

AdultMalePharmacologyCholestyramineAnticoagulant effectDose-Response Relationship DrugChemistryCholestyramine Resin4-HydroxycoumarinsMiddle AgedPharmacologyPhenprocoumonLiverPharmacokineticsEnterohepatic CirculationPhenprocoumonmedicineHumansPharmacology (medical)Enterohepatic circulationHalf-Lifemedicine.drugClinical Pharmacology & Therapeutics
researchProduct

Incidence of venous thromboembolism in patients undergoing thoracotomy for lung cancer

2008

Limited information exists on the incidence of symptomatic venous thromboembolism (vTE) in patients undergoing chest surgery for lung cancer. Several factors increase the thromboembolic risk in patients undergoing surgery for lung cancer: the intrinsic procoagulant effect of cancer,extensive surgical intervention, dependent limb position in the operating room, and vessel injury consequent to the operation. Furthermore,these patients might be especially vulnerable to pulmonary embolism (PE) because of the loss of lung tissue and the presence of chronic obstructive pulmonary disease and cardiovascular diseases caused by smoking.t Older studies found a very high incidence of thromboembolic eve…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentSeverity of Illness Indexvenous thromboembolism thoracotomySettore MED/15 - Malattie Del SangueCohort StudiesAge DistributionPostoperative ComplicationsRisk FactorsmedicineHumansMulticenter Studies as TopicThoracotomySex DistributionLung cancerPneumonectomyAgedNeoplasm StagingRetrospective StudiesAged 80 and overOntariobusiness.industryVascular diseaseIncidence (epidemiology)IncidenceRespiratory diseaseCancerAnticoagulantsRetrospective cohort studyVenous ThromboembolismMiddle Agedmedicine.diseasePrognosisSurvival AnalysisSurgeryVenous thrombosisItalyThoracotomyFemaleSurgerybusinessPulmonary EmbolismCardiology and Cardiovascular MedicineThe Journal of Thoracic and Cardiovascular Surgery
researchProduct